ARTERIAL HYPERTENSION IN SYSTEMIC VASCULITIS: CLINICAL FEATURES AND PRINCIPLES OF PATHOGENETIC THERAPY. PART II. POSSIBILITIES OF OPTIMIZING OF ANTIHYPERTENSIVE TREATMENT
https://doi.org/10.20996/1819-6446-2013-9-6-672-677
Abstract
The article deals with the problem of arterial hypertension in systemic vasculitis. Data on the principles of antihypertensive treatment of systemic vasculitis are presented. The possibilities of pharmacotherapy and surgical treatment of these diseases are discussed separately.
About the Authors
E. A. Praskurnichy
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Russian Federation
N. G. Poteshkina
Russian National Research Medical University named after N.I. Pirogov, Moscow
Russian Federation
Russian Federation
References
1. de la Cueva J, Picon R, Gonzales M, Beltran J.A case of Takayasu's disease presenting as severe secondary hypertension, with angiographic improvement following medical treatment. Rev Esp Cardiol 2010;63(3):365-7.
2. Deng F, Lu L, Zhang Q, et al. Henoch-Sch nlein purpura in childhood: treatment and prognosis. Analysis of 425 cases over a 5-year period. Clin Rheumatol 2010;29(4):369-74.
3. Chikhladze NM, Sivakova OA, Gaman SA et al. Arterial hypertension in patients with nonspecific aortoarteritis with renal artery lesions. Systemnie Gypertensii 2008; 2: 64-66. Russian (Чихладзе Н.М., Сивакова О.А., Гаман С.А. и др. Артериальная гипертония у больных неспецифическим аортоартериитом с поражением почечных артерий. Системные Гипертензии 2008; 2: 64-66).
4. Ham SW, Kumar SR, Rowe VL, Weaver FA. Disease progression after initial surgical intervention for Takayasu arteritis. J Vasc Surg 2011;54(5):1345-51.
5. Panoulas V.F., Metsios G.S., Pace A.V. et al. Hypertension in rheumatoid arthritis. Rheumatology (Ox- ford) 2008;47:1286-98.
6. Myasoedova EE. Prevalence and risk factors of hypertension in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiia 2012; 51 (2): 31-4. Russian (Мясоедова Е.Е. Распространенность и факторы риска артериальной гипертензии при ревматоидном артрите. Научно-Практическая Ревматология 2012; 51(2): 31-4).
7. Leonova MV, Maneshina OA. Smoking and drugs for the treatment of cardiovascular diseases : pharmacological and pharmacodynamic aspects. Serdtse 2007; 6 (6): 316-21. Russian (Леонова М.В., Манешина О.А. Курение и лекарственные средства для лечения сердечно-сосудистых заболеваний: фармакологические и фармакодинамические аспекты. Сердце 2007; 6(6): 316-21).
8. Gilyarevsky SR. The effectiveness of alternative and complementary treatments for cardiovascular disease : how demonstrative used intervention. Serdtse 2007; 6 (6): 322-32. Russian (Гиляревский С.Р. Эффективность применения альтернативного и комплементарного лечения сердечно-сосудистых заболеваний: насколько доказательны используемые вмешательства. Сердце 2007; 6(6): 322-32).
9. Popkova TV, Novikova DS, Nasonov EL. Cardiovascular risk factors in rheumatic diseases: relationship with inflammation. Consilium Medicum 2010; (12) :112-8. Russian (Попкова Т.В., Новикова Д.С., Насонов Е.Л. Кардиоваскулярные факторы риска при ревматических заболеваниях: связь с воспалением. Consilium Medicum 2010;(12):112-8).
10. National guidelines for the diagnosis and treatment of hypertension (4th revision) . Sistemnie Gypertensii 2010 (3) : 5-26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26).
11. Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-053
12. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013;34(28):2159-219
13. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106: 2422-27.
14. Zanchetti A, Rosei EA, Dal PC et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intimamedia thickness. J Hypertens 1998;16:1667-76
15. Pope JE, Anderson JJ, Felson DT. A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure. Archives of Internal Medicine 1993; 153 (4): 477-84.
16. Johnston AG, Ngyuyen TV, Day RO. Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.
17. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65:1991.
18. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.
19. Brown N J, Vaughan DE. Angiotensin-Converting Enzyme Inhibitors. Circulation 1998; 97: 1411-20.
20. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637.
21. Xu J, Carretero OA, Shesely EG et al. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in mice. Exp Physiol 2009; 94 (3): 322-9.
22. Zhu L, Carretero OA, Xu J et al. Angiothensin II type receptor-stimulated activation of plasma prekallikrein and bradykinin release: role of SHP-1.Am. J Physiol Heart Circ Physiol 2012; 302 (12): H 2553-59.
23. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensinconverting enzyme inhibitors and angiotensin II receptors blockers for treating essential hypertension. Ann Intern Med 2008; 148 (1): 16-29.
24. Mimran A, Ribstein J, DuCailar G. Converting enzyme inhibitors and renal function in essential and renovascular hypertension. Am J Hypertens 1991; 4:7S
25. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136:604.
26. Weir MR. Progressive renal and cardiovascular disease: optimal treatment strategies. Kidney Int 2002; 62:1482.
27. Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163:1417.
28. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49:12.
29. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32(22):2851-906.
30. Bokeria LA, Abdulgasanov RA. Arterial hypertension in systemic vasculitis, vasculopathy and kollagenozah. Moscow: AN NTSSSH n.a. A.N. Bakuleva RAMS; 2007;122. Russian (Бокерия Л.А., Абдулгасанов Р.А. Артериальные гипертензии при системных васкулитах, васкулопатиях и коллагенозах. М.: НЦССХ им А.Н. Бакулева РАМН; 2007;122).
Review
For citations:
Praskurnichy E.A., Poteshkina N.G. ARTERIAL HYPERTENSION IN SYSTEMIC VASCULITIS: CLINICAL FEATURES AND PRINCIPLES OF PATHOGENETIC THERAPY. PART II. POSSIBILITIES OF OPTIMIZING OF ANTIHYPERTENSIVE TREATMENT. Rational Pharmacotherapy in Cardiology. 2013;9(6):672-677. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-6-672-677
Views:
962
Email this article 